BIIB 015
Alternative Names: Anti-CRIPTO; Anti-Cripto mAB; Anti-Cripto-DM4; BIIB015Latest Information Update: 14 Feb 2024
At a glance
- Originator Biogen Idec
- Developer Biogen
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 01 Jun 2011 Biogen Idec completes a phase I trial in Solid tumours in the USA (NCT00674947)